Taewoong Co., Ltd
KKRX:04449025,300.00
KRW
-950.00
(-3.62%)
ISIN
KR7044490001
Return %
Stock
S&P 500
1Y
-16.09
14.20
3Y
67.88
81.12
5Y
102.40
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hui-Sang Jang
- Full Time Employees
- 452
- Sector
- Producer manufacturing
- Industry
- Metal fabrication
- Address
- 67, Noksansandan 27-ro Busan BU South Korea
- IPO Date
- Nov 8, 2001
- Website
- taewoong.com
- Similar Companies
- Business
- Taewoong Co.,Ltd operates as a comprehensive steel company primarily engaged in the manufacture and sale of open-die forgings and seamless rolled rings, catering to industries including wind power generation, oil and gas, petrochemicals, industrial machinery, nuclear power, shipbuilding, and aerospace. The company produces steel products with an annual capacity of 700,000 tons of steelmaking and 350,000 tons of forged products, specializing in large forged parts and ring rolled products in various steel grades such as carbon steel, low alloy steel, stainless steel, and aluminum alloy. Taewoong has developed an integrated production system from raw materials to forging and machining, highlighted by its capability to produce the world's largest Ø1000 round blooms and advanced rolled ring components such as tower flanges, yaw bearings, and gear rims for wind energy applications. Operating since 1981 and headquartered in Busan, South Korea, Taewoong serves both domestic and international markets. In recent major developments, Taewoong Medical, a subsidiary focused on gastrointestinal medical devices manufacturing metallic stents and endoscopic instruments, was acquired by Olympus Corporation in early 2024, integrating Taewoong Medical’s endoscopic RFA and GI metallic stent portfolio into Olympus's Therapeutic Solutions Division to strengthen its GI EndoTherapy capabilities globally. Additionally, Taewoong Co.,Ltd has been involved in strategic partnerships such as the exclusive collaboration with Mauna Kea Technologies in 2025 to expand commercial activities in the U.S. pancreas cyst diagnostics market, combining therapeutic and diagnostic technologies for enhanced patient care. The company continues to modernize and revamp its production capabilities, including upgrades to its ring rolling mill machinery, reinforcing its position in the global steel forging industry. Taewoong Co.,Ltd’s product portfolio includes open-die forgings; seamless rolled rings; large forged steel components such as main shafts, tower flanges, inner and outer rings for pitch bearings, yaw bearings, gear rims, and slewing rings mainly for wind turbine applications; and steel products tailored for energy, marine, and industrial sectors. The company emphasizes eco-friendly production technologies including electric arc furnaces and vacuum degassing and casting technologies, maintaining high-tech steelmaking standards. Taewoong also operates across multiple geographies, supplying steel and forged components worldwide, with significant sales in South Korea, Asia, Europe, and America. Founded in 1981, headquartered in Busan, South Korea, Taewoong Co.,Ltd targets capital goods and industrial machinery sectors, serving customers requiring high-specification steel and forged products for critical infrastructure and industrial equipment. The company’s scale, high technological capabilities, and recent strategic alignments underscore its commitment to innovation and expanding global market presence.